The FDA granted accelerated approval to the second-generation BTK inhibitor acalabrutinib, which, because of its increased selectivity, seems to cause fewer side effects than ibrutinib, previously the only BTK inhibitor on the market.

中文翻译：

---

Acalabrutinib获准用于MCL

FDA批准了第二代BTK抑制剂acalabrutinib的加速批准，由于其选择性的提高，它引起的副作用似乎比以前市场上唯一的BTK抑制剂ibrutinib少。